CRISPR Therapeutics (NASDAQ:CRSP) Upgraded at TD Cowen
TD Cowen upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) from a sell rating to a hold rating in a research note issued to investors on Wednesday, MarketBeat reports. TD Cowen currently has $35.00 price target on the stock. Several other research analysts have also commented on the company. Barclays lowered their price target […]
TD Cowen upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) from a sell rating to a hold rating in a research note issued to investors on Wednesday, MarketBeat reports. TD Cowen currently has $35.00 price target on the stock. Several other research analysts have also commented on the company. Barclays lowered their price target […]
